Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Department of Labor Wants to Study Possible Occupation-Cancer Links

February 1, 1995
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 2
Volume 4
Issue 2

WASHINGTON--The US Department of Labor, Occupational Safety and Health Administration (OSHA) wants more money to study the possible associations between occupation and the incidence of cancer.

WASHINGTON--The US Department of Labor, Occupational Safety andHealth Administration (OSHA) wants more money to study the possibleassociations between occupation and the incidence of cancer.

Testifying before the President's Cancer Panel, Peter Infante,DDS, DrPH, director of OSHA's Office of Standards Review, saidthat OSHA needs the information to set the workplace standardfor permissible levels of certain substances believed to be carcinogens.

Dr. Infante said that 22 agents, proven carcinogenic by the WorldHealth Organization's International Agency for Research on Cancer(IARC), are still used in industry. In addition, 42 other industrialcompounds and agents are listed by the IARC as "probable"causes of human cancer on the basis of animal or epidemiologicevidence.

Articles in this issue

FTC Advised to List Tar and Nicotine Levels Directly on Cigarette Packages
Multidisciplinary Approach Urged For Pain Relief
FDA Approves New Indication for Neupogen: Chronic Neutropenia
Department of Labor Wants to Study Possible Occupation-Cancer Links
Undertreatment of Cancer-Related Pain May Be Tied to Physicians' Fear of Addiction to Drugs
Navelbine Is Now Available for Use in Inoperable Advanced Stage NSCLC
ASH Panel: How Many Hemotologists/Oncologists Are Enough?
Mammography Van Brings Breast Cancer Screening to the Workplace
FDA to Build $600 Million Campus
Finasteride Studied as Prostate Ca Preventive
Panel Fails to Recommend Taxotere as Treatment for Breast and Lung Cancer
Thrombopoietin Raises Platelet Counts in Animals
Major Cancer Centers Form Network to Negotiate With Insurers
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
Liposomal Tretinoin in Phase II/III Trials in Kaposi's Sarcoma Patients
Recent Videos
2 experts in this video
2 experts in this video
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
Related Content
Advertisement

QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer

QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer

Tim Cortese
May 28th 2025
Article

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Russ Conroy
May 28th 2025
Article

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

EBC-129 Receives FDA Fast-Track Designation for PDAC

Roman Fabbricatore
May 28th 2025
Article

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.


Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC

Roman Fabbricatore
May 28th 2025
Article

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

Related Content
Advertisement

QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer

QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer

Tim Cortese
May 28th 2025
Article

A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.


Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.

Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025

Rachel N. Grisham, MD;MinhTri Nguyen, MD;Eric Singhi, MD;Douglas Adkins, MD;Benjamin Garmezy, MD
May 26th 2025
Podcast

Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.


Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.

ASCO 2025: Key Anticipated Updates Across Cancer Care

Russ Conroy
May 28th 2025
Article

Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.


Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.

Leveraging Artificial Intelligence to Bolster Equitable Cancer Care

Viviana Cortiana, MS4;Yan Leyfman, MD
May 19th 2025
Podcast

Authors of a manuscript published in ONCOLOGY® discuss how artificial intelligence may help with cancer detection and improving various patient outcomes.


Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Oncology Annual Meeting.

EBC-129 Receives FDA Fast-Track Designation for PDAC

Roman Fabbricatore
May 28th 2025
Article

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.


Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC

Roman Fabbricatore
May 28th 2025
Article

Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.